氨磷汀联合三氧化二砷与维生素C治疗高危骨髓增生异常综合征的疗效分析

Efficacy analysis of amifostine combined with arsenic trioxide and vitamin C in the treatment of patients with high-risk myelodysplastic syndromes

目的观察氨磷汀联合三氧化二砷（As2O3）与维生素C治疗高危骨髓增生异常综合征的疗效。方法15例患者应用氨磷汀500mg／d，静脉滴注，As20310mg／d，静脉滴注，结束4h后应用维生素C2．0g／d，静脉滴注，每周连续用药5d，间隔2d，4周为1个疗程。结果完全缓解2例（13．3％），部分缓解3例（20．0％），血液学改善5例（33．3％），5例（33．3％）无效，总有效率为66．7％。结论氨磷汀联合As203与维生素C治疗高危骨髓增生异常综合征疗效确切，且未见明显不良反应。

Objective To observe the efficacy of amifostine combined with arsenic trioxide and vitamin C on patients with high-risk myelodysplastic syndromes. Methods Fifteen patients received am- ifostine 500 mg/d, arsenic trioxide 10 mg/d by intravenous infusion and then reeieved vitamin C 2. 0 g/ d by intravenous infusion after 4 hours, continuous medication for 5 days a week, interval 2 days, 4 weeks repeated for a course. Results Complete remission in 2 cases （ 13.3% ）, partial remission in 3 cases （20.0%）, hematologic improved in 5 cases（33.3% ）, invalid in 5 eases（33.3% ）, and the total effec- tive rate was 66.7%. Conclusions Amifostine combined with arsenic trioxide and vitamin C is effective and has no significant adverse reactions in treating high-risk myelodysplastic syndromes.